研究挑战长期存在的关于过度活跃膀胱药物与痴呆症风险的担忧
Study challenges long-held fears about overactive bladder drugs and dementia
一项发表在JAMA Network Open的研究发现,抗胆碱能药物(常用于治疗过度活跃膀胱)与痴呆症的风险相比,与β-3激动剂(较新的药物类别)并无显著差异。研究结果表明,OAB本身及其神经机制可能是痴呆症早期预警信号。
研究挑战了长期存在的关于抗胆碱能药物与痴呆症风险的担忧,为OAB的治疗提供了新的视角。
New research published in JAMA Network Open finds anticholinergic medications, commonly prescribed for overactive bladder (OAB), may not increase dementia risk after all compared to beta-3 agonists, the newer drug class that has been presumed to be safer for the brain.
Researchers at University Hospitals Cleveland Medical Center Urology Institute used Epic Cosmos, a national electronic health record database, to follow 830,393 adults ages 40 to 90 who were newly treated for OAB between 2012 and 2025. Dementia rates were similar across drug classes and individual medications.
The study demonstrates that in patients with OAB, anticholinergic medication, a foundational, second-line pharmacological treatment for the condition, does not carry a greater long-term risk of dementia than beta-3 agonists. Drugs in the latter class were previously believed to pose a lower risk.
Bladder symptoms as an early warning
This reverses a long-held belief that one group of drugs is riskier than the other; instead, the findings align with the idea that OAB itself and the neurologic mechanisms that lead to urinary incontinence may be early warning signs of neurodegenerative processes associated with dementia.
According to lead author David Sheyn, M.D., a urogynecologist at University Hospitals Cleveland Medical Center Urology Institute, this is potentially good news: "If some cases of OAB are truly an early symptom of dementia, we might be able to use it as an early marker of frontal cortical dysfunction to identify dementia earlier and perhaps look for and stop that common mechanism or at least intervene early enough to make a significant impact on the disease process."
Clinical caution and study limits
He cautions, though, that these results are still new and will require reproduction prior to a change in clinical guidelines, and beta-3 agonists are still considered the better choice whenever possible.
Several well-done observational studies have linked anticholinergic medications to dementia, and that concern is often shared with patients, which may make them afraid to take medication that could help them.
Sheyn said he wanted to study this because the process that causes dementia often starts decades before dementia symptoms show up, and most studies suggesting these bladder medications cause dementia followed patients for five years or less.
The study compared drug classes and did not include patients who took no medication, so it cannot show that these drugs carry no risk. It also cannot prove that OAB is an early sign of dementia on its own, only that the pattern fits that explanation.
Publication details
David Sheyn et al., Drug Therapies and Incidence of Dementia Among Adults With Overactive Bladder, JAMA Network Open (2026). DOI: 10.1001/jamanetworkopen.2026.42026
Journal information: JAMA Network Open
Who's behind this story?
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: Study challenges long-held fears about overactive bladder drugs and dementia (2026, November 9) retrieved 9 November 2026 from https://medicalxpress.com/news/2026-11-held-overactive-bladder-drugs-dementia.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com